ELVN Stock Analysis: Buy, Sell, or Hold?
ELVN - Enliven Therapeutics, Inc. Common Stock
$50.87
-0.22 (-0.43%)
▼
5d:
+1.72%
30d:
+37.49%
90d:
+12.25%
BUY
MODERATE Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 12, 2026
29d
Smart Money Distribution
None View Scanner →
Strength: 7.8/10
Get Alerted When ELVN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ELVN shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: ELVN shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: ELVN is currently trading at $50.87, which is considered extended relative to its 30-day fair value range of $37.48 to $49.41.
Technical Outlook: Technically, ELVN is in a strong uptrend. The price is approaching resistance at $52.39. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ELVN has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $66.00 (+29.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ELVN is in a strong uptrend. The price is approaching resistance at $52.39. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ELVN has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $66.00 (+29.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$37.48 -
$49.41
Company Quality Score
63/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 29.7% below Wall St target ($66.00)
Trading Range Analysis
30-Day Trading Range
$37.48 -
$49.41
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$47.45
Resistance Level
$52.39
Current Trend
Strong Uptrend
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-21.88
Wall Street Target
$66.00
(+29.7%)
Share & Embed Analysis
Last updated: July 13, 2026 6:01 PM ET
Data refreshes hourly during market hours. Next update: 7:01 PM
Data refreshes hourly during market hours. Next update: 7:01 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ELVN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
5
Sells
Net
INSIDERS SELLING
Recent Transactions
Benjamin Hohl
SELL
10000 shares
2026-03-06
Richard A Heyman
SELL
1230 shares
2026-02-17
Joseph P Lyssikatos
SELL
5000 shares
2026-02-06
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$441 | 60 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 67 BUY |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$258 | 67 BUY |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$22 | 59 HOLD |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
12 analysts |
$128 | 59 HOLD |
Advanced ELVN Option Strategies
Professional options setups generated by AI based on today's ELVN price and gamma walls.
